Deferred registration: Phase I Trial: MAC code 'MAC215'

Deferred registration: Phase I Trial: MAC code 'MAC215' [Full scientific title to be added on or before the deferral expiry date]

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10994097

Enrollment

Registered

2026-06-17

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Exclusion criteria

Exclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Design outcomes

Primary

Measure	Time frame
[Outcome] measured using [measure] at [timepoint]. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.	—

Countries

England, Scotland, United Kingdom

Contacts

Public ContactAdam Uchimoto

auchimoto@neurocrine.com-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 3, 2026